OPT vs. CRDF, KOD, IPHA, IPSC, ABOS, ELEV, CMPX, PSTX, XFOR, and GNFT
Should you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Cardiff Oncology (CRDF), Kodiak Sciences (KOD), Innate Pharma (IPHA), Century Therapeutics (IPSC), Acumen Pharmaceuticals (ABOS), Elevation Oncology (ELEV), Compass Therapeutics (CMPX), Poseida Therapeutics (PSTX), X4 Pharmaceuticals (XFOR), and Genfit (GNFT). These companies are all part of the "biological products, except diagnostic" industry.
Cardiff Oncology (NASDAQ:CRDF) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, community ranking, earnings, valuation and risk.
16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 56.0% of Opthea shares are held by institutional investors. 6.3% of Cardiff Oncology shares are held by insiders. Comparatively, 3.2% of Opthea shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Cardiff Oncology and Cardiff Oncology both had 2 articles in the media. Opthea's average media sentiment score of 0.00 equaled Cardiff Oncology'saverage media sentiment score.
Cardiff Oncology received 22 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 61.67% of users gave Cardiff Oncology an outperform vote while only 50.00% of users gave Opthea an outperform vote.
Cardiff Oncology has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Opthea has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
Cardiff Oncology currently has a consensus price target of $10.50, suggesting a potential upside of 163.16%. Opthea has a consensus price target of $14.00, suggesting a potential upside of 284.62%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Opthea is more favorable than Cardiff Oncology.
Cardiff Oncology has higher revenue and earnings than Opthea.
Opthea has a net margin of 0.00% compared to Opthea's net margin of -8,492.01%. Cardiff Oncology's return on equity of 0.00% beat Opthea's return on equity.
Summary
Cardiff Oncology and Opthea tied by winning 6 of the 12 factors compared between the two stocks.
Get Opthea News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
